Drug resistance in cytomegalovirus: Current knowledge and implications for patient management

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue SUPPL. 1, 1996, Pages

  Crumpacker, Clyde S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALACICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CROSS RESISTANCE; CYTOMEGALOVIRUS INFECTION; DNA HYBRIDIZATION; DRUG MECHANISM; GENE MUTATION; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT PLANNING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, MICROBIAL; GANCICLOVIR; HUMANS; IMMUNOCOMPROMISED HOST; MICROBIAL SENSITIVITY TESTS; TRANSPLANTATION IMMUNOLOGY;

CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029835063     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993;329:1922-6.
2. Drew WL. Cytomegalovirus infection in patients with AIDS. J Infect Dis 1988;158:449-56.
3. Polis MA. Forscarnet and ganciclovir in the treatment of Cytomegalovirus retinitis. J Acquir Immune Defic Syndr 1992;5(suppl 1):S3-10.
4. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of Cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665-73.
5. SOCA Research Group and the ACTG. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for Cytomegalovirus retinitis. N Engl J Med 1992;326:213-20.
6. SOCA Research Group and the ACTG. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed Cytomegalovirus retinitis in patients with AIDS. Arcli Oplitlialmol 1996;114:23-33.
7. Polis MA, Spooner KM, Baird BK. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and Cytomegalovirus viruria. Antimicrob Agents Cheinothcr 1995;39: 882-6.
8. Lalezari J, Holland G, Stagg R, et al. A randomized, controlled study of cidofovir (CDV) for relapsing Cytomegalovirus retinitis (CMV-R) in patients with AIDS [Abstract]. ProcICAAC, San Francisco, 1995:LB-9.
9. Spector SA, McKinley G, Drew WL, et al. A randomized, double-blind study of the efficacy and safety of oral ganciclovir for the prevention of Cytomegalovirus disease in HIV-infected persons [Abstract]. Proc 2nd National Conference on Human Rctroviruses and Related Infections, Washington, DC, 1995.
10. Spector SA, McKinley GF, Lalezari JP, et al. A randomized, double-blind trial of oral ganciclovir for the prevention of Cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;332:1491-7.
11. Hibberd PL, TolkofT-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent Cytomegalovirus disease in Cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med 1995; 123:18-26.
12. Balfour HH, Chace BA, Stapleton JT. A randomized, placebo-controlled trial of oral acyclovir for the prevention of Cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320:1381.
13. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of Cytomegalovirus infection and disease after allogeneic marrow transplantation. A' Engl J Med 1988;318:70.
14. Winston DJ, Winn D, Shaked A, et al. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346:69-74.
15. Feinberg J, Cooper D, Hurwitz S, et al. Phase III study of valacyclovir (VACV) for cytomegalovirus (CMV) prophylaxis in patients with advanced HIV disease [Abstract]. Proc ICAAC, San Francisco, 1995:1214.
16. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Mw
17. Boeckh M, Gooley T, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized doubleblind study. Blood(\n press).
18. Gerna G, Furione M, Baldanti F, et al. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. BrJHcmalol 1995;91:674-83.
19. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994;343:749-53.
20. Biron KK, Fyfe JA, Stanat SC, et al. A human cytomegalovirus mutant resistant to the nucleoside analog 9-{[2-hydroxy-1 (hydroxymethyl)ethoxy] Jguanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci USA 1986; 83:8769-73.
21. Erice A, Chou S, Biron KK, et al. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320: 289-93.
22. Knox KK, Drobyski WR, Carrigan DR. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 1991; 337:1292-3.
23. Leport C, Puget S, Pepin JM, et al. Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus. J Infect Dis 1993; 168:1329-30.
24. Flores-Aguilar M, Kuppermann BD, Quiceno JI, et al. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology 1993; 100: 1022-30.
25. Smith IL, Jiles RE, Spector SA. Reduced foscarnet susceptibility in clinical human cytomegalovirus isolates is conferred by the mutations in the viral polymerase [Abstract]. The 20th International Herpesvirus Workshop, Groningen, The Netherlands, 1995:295.
26. Gerna G, Sarasini A, Percivivalle E, et al. Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culturepositive blood samples. J Clin Microbiol 1995;33: 738-41.
27. Sarasini A, Baldanti F, Furione M, et al. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. J Med Virol 1995;47:237-44.
28. Smith IL, Cherrington JM, Jiles RE, et al. Multidrug resistance in a human cytomegalovirus isolate is attributable to DNA polymerase alterations (submitted for publication).
29. Stanat SC, Reardon JE, Erice A, et al. Ganciclovirresistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991;35:2191-7.
30. Gerna G, Baldanti F, Zavattoni M, et al. Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antiviral Res 1992;19:333-45.
31. Plotkin SA, Drew WL, Felsenstein D, et al. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985; 152:833-4.
32. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-9.
33. Dankner WM, Scholl D, Stanat SC, et al. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J Virol Methods 1990;28:293-8.
34. Field K, Biron KK. The End of Innocence revisited: resistance of herpesviruses to antiviral drugs, Clin Microbiol Rev 1994;7:1-13.
35. Drew WL, Miner R, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993;1:179-85.
36. Crumpacker CS, Kowalsky PN, Oliver SA, et al. Resistance of Herpes simplex virus to 9[-(2-hydroxy-1-hydroxymethyl)ethoxyl]methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus. Proc Natl Acad Sci USA 1984;81:1556-60.
37. Sullivan V, Talarico CL, Stanat SC, et al. A protein kinase homologue controls phosphorylation ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162-4.
38. Chou S, Erice A, Jordan MC, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995;171:576-83.
39. Chou S, Guentzel S, Michels KR, et al. Frequency of UL97 phototransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995;172:239-42.
40. Lurain NS, Spafford LE, Thompson KD. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol 1994;68: 4427-31.
41. Baldanti F, Silini E, Sarasini A, et al. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol 1995;69:796-800.
42. Hanson MN, Preheim LC, Chou S, et al. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob Agents Chemother 1995; 39:1204-5.
43. Chou S, unpublished data.
44. Baldanti F, Sarasinia A, Silini E, et al. Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. Scand J Infect Dis 1995;suppl 99:1031.
45. Sullivan V, Biron K.K., Talarico C, et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Cliemother 1993;37:19-25.
46. Lurain NS, Thompson KD, Holmes EW, et al. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992; 66:7146-52.
47. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996;70:1390-5.
48. Drew VVL, I ves D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-62.
49. Squires K et al. [submitted for publication].
50. Buhles W, Drew WL, Miner D, et al. Resistance rates following treatment with iv and oral ganciclovir (GCV) [Abstract]. ProcICAAC, Orlando, 1994:H30.
51. Jokela J, Wenrib D, Zaleznik D, et al. Isolation of a ganciclovir resistant isolate of CM V from the cerebrospinal fluid of a patient with progressive polyradiculopathy syndrome [Abstract]. Proc ICAAC, Orlando, 1994:H97.
52. Wolf DG, Lee DJ, Spector SA. Detection of human cytomegaolovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Antimicrob Agents Chemother 1995; 39:2552-4.
53. Eidelberg D, Sotrel A, Vogel H, et al. Progressive polyradiculopathy in acquired immune deficiency syndrome. Neurology 1986; 36:912-6.
54. Fuller GN. Cytomegalovirus and the peripheral nervous system in AIDS. J Acquir Immun Defic Syndr 1992;5(suppl):S33-6.
55. Miller RG, Storey JR, Greco CM. Ganciclovir in the treatment of progressive AIDS-related polyradiculopathy. Neurology 1990;40:569-74.
56. Fuller GN, Gill SK, Guliloff RJ, et al. Ganciclovir for lumbrosacral polyradiculopathy in AIDS. Lancet 1990; 1:48-9.
57. Enting R, deGans J, Reiss P, et al. Ganciclovir/foscarnet for cytomegalovirus meningoencephalitis in AIDS. Lancet 1992; 340:559-60.
58. Drew WL, Buhles WC. Nucleosides and foscarnetclinical aspects. In: Richman D, ed. Antiviral drug resistance. England: John Wiley and Sons, 1996:153-66.
59. 58a.Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. Cytomegalovirus (CMV) culture results, drug resistance and clinical outcome in patients with AIDS and CMV retinitis treated with either foscarnet or ganciclovir. Ann Intern Med [submitted for publication].
60. Miner R, Drew WL, Lalezari J, et al. Human cytomegalovirus (HCM V) does not develop resistance following short term treatment with cidofovir [Abstract]. Proc 2nd National Conference on Human Retrovinises, Washington, DC, 1995.
61. Boivin G, Erice A, Crane DD, et al. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993; 168:332-5.
62. Slavin MA, Bindra RR, Cleaves ÇA, et al. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Anlimicrob Agents Chemotlier 1993; 37:1360-3.
63. Reusser P, Cordonnier C, Einsele H, et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 1996; 17:813-17.
64. Boeckh M, Gooley T, Goodrich J, et al. Increased incidence of late cytomegalovirus disease in patients who received ganciclovir prophylaxis after allogeneic marrow transplantation [Abstract]. Proc Eighth International Symposium on Infections in thelmmunocompromisedllost, Davos, Switzerland, 1994:60.
65. Wolf DG, Smith IL, Lee D, et al. Mutations in human cytomegalovirus UL97 confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 1995;95:257-63.
66. Alain S, Mazeron MC, Pepin JM, et al. Rapid detection of cytomegalovirus strains resistant to ganciclovir through mutations within the gene UL97. Mol Cell Probes 1993;7:487-95.
67. Pepin JM, Simon F, Dussault A, et al. Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures. J Clin Microbiol 1992; 30:2917-20.
68. Crumpacker CS, Landry M, Stanat SC, et al. Development of a consensus assay to determine susceptibility of clinical isolates of CM V to antiviral therapy [Abstract]. Proc 3rd National Conference on Retrovinises and Opportunistic Infections, Washington, DC, 1996:164.
69. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992;358:160-2.
70. Boivin G, Chou S, Quirk MR, et al. Detection of ganciclovir resistance mutations and quantification of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996; 173:523-8.
71. Drew WL, Miner RC, Craget M, et al. Prevalence of ganciclovir-resistant cytomegalovirus during oral ganciclovir prophylaxis [Abstract]. Proc 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996:LB16.
72. Drew WL, Anderson R, Lang W, et al. Failure of highdose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients. J Acquir Immune Defic Syndr 1995; 8:289-91.
73. Smith IL, Jiles RE, Spector SA. Reduced cytomegalovirus susceptibility to foscarnet is found in ganciclovir resistant isolates and foscarnet. resistance is conferred by mutations in the CMV polymerase [Abstract]. Proc ICAAC, San Francisco, 1995:H115.
74. Tatarowicz WA, Lurain NS, Thompson KD. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J Infect Dis 1992; 166:904-7.
75. Gerna G, Parea M, Percivalle E, et al. Human cytomegalovirus viraemia in HI V-l-seropositive patients at various clinical stages of infection. AIDS 1990;4:1027-31.
76. Gerna G, Furione M, Baldanti F, et al. Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol 1994; 32:2709-17.
77. Bek B, Boeckh M, Lepenies J, et al. High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol 1996; 34: 457-9.
78. + lymphocyte counts below 100/μ1 of blood: features and relations to risk of subsequent CMV retinitis. J Acquir Immune Defic Syndr 1995; 10:324-30.
79. Erice A, Crumpacker CS, Britt W, et al. Quantification of cytomegalovirus load in blood fractions of patients with AIDS: a comparative study of different laboratory methods [Abstract]. Proc 3rd National Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996:166.
80. Wolitz R, et al. Presentation and treatment outcome of CMV retinitis after oral ganciclovir prophylaxis [Abstract]. Proc 3rd National Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996:9.
81. Grossi P, Minoli L, Percivalle E, et al. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995;59:847-51.
82. Locatelli F, Percivalle E, Comoli P, et al. Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemia on patients' outcome. Br J Haematol 1994;88:64-71.